HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese switch hurts Bayer

This article was originally published in OTC Bulletin & The Rose Sheet

Executive Summary

An “unexpected” move by the China Food and Drug Administration (CFDA) to reverse-switch two of its leading OTC products, in combination with “persistently weak business development in the US”, caused Bayer’s Consumer Health sales to fall by 2.9% to €5.86 billion in 2017, the German company reported.

Advertisement

Related Content

Bayer Bullish On Consumer Health’s Prospects Despite ‘Challenging’ 2018
Bayer Consumer Chief Identifies 'Root Causes' Of Slump, Initiates Growth 'Fix'
Bayer's Consumer Chief Initiates Turnaround Plan In Bid To Return Troubled Business To Growth
Bayer Consumer Health Yet To Turn Corner Due To Supply, Innovation Detours
Bayer Consumer Health Yet To Turn Corner Due To Supply, Innovation Detours

Topics

Advertisement
UsernamePublicRestriction

Register

RS122061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel